Difference between revisions of "Endometrial cancer"
m |
|||
Line 1: | Line 1: | ||
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | ||
− | Is there a regimen missing from this list? | + | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> |
− | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | = | + | =Endocrine therapy for endometrioid histologies= |
==Anastrozole (Arimidex) {{#subobject:534a|Regimen=1}}== | ==Anastrozole (Arimidex) {{#subobject:534a|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 16: | Line 16: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | + | ===Regimen {{#subobject:8c4e67|Variant=1}}=== | |
− | <span | + | {| border="1" style="text-align:center;" !align="left" |
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.gynecologiconcology-online.net/article/S0090-8258(00)95865-7/abstract Rose et al. 2000] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 23: | Line 28: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Endocrine therapy==== | ||
*[[Anastrozole (Arimidex)]] 1 mg PO once per day | *[[Anastrozole (Arimidex)]] 1 mg PO once per day | ||
Line 29: | Line 36: | ||
===References=== | ===References=== | ||
− | # Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000 Aug;78(2):212-6. [http://www. | + | # Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000 Aug;78(2):212-6. [http://www.gynecologiconcology-online.net/article/S0090-8258(00)95865-7/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10926805 PubMed] |
==Medroxyprogesterone acetate (MPA) {{#subobject:6c7bb9|Regimen=1}}== | ==Medroxyprogesterone acetate (MPA) {{#subobject:6c7bb9|Regimen=1}}== | ||
Line 52: | Line 59: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Endocrine therapy==== | |
*[[Medroxyprogesterone acetate (MPA)]] 200 mg PO once per day | *[[Medroxyprogesterone acetate (MPA)]] 200 mg PO once per day | ||
Line 66: | Line 73: | ||
|} | |} | ||
===Regimen {{#subobject:334b8c|Variant=1}}=== | ===Regimen {{#subobject:334b8c|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.gynecologiconcology-online.net/article/S0090-8258(03)00651-6/abstract Whitney et al. 2004] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 73: | Line 84: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Endocrine therapy==== | ||
*[[Medroxyprogesterone acetate (MPA)]] 100 mg PO BID on even-numbered weeks (for example, week 2, 4, 6, etc.) | *[[Medroxyprogesterone acetate (MPA)]] 100 mg PO BID on even-numbered weeks (for example, week 2, 4, 6, etc.) | ||
*[[Tamoxifen (Nolvadex)]] 20 mg PO BID | *[[Tamoxifen (Nolvadex)]] 20 mg PO BID | ||
− | ''' | + | '''Given until progression of disease or unacceptable toxicity''' |
===References=== | ===References=== | ||
− | # Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB; Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):4-9. [http://www. | + | # Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB; Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):4-9. [http://www.gynecologiconcology-online.net/article/S0090-8258(03)00651-6/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/14751130 PubMed] |
==Megestrol acetate (Megace) {{#subobject:4b50ea|Regimen=1}}== | ==Megestrol acetate (Megace) {{#subobject:4b50ea|Regimen=1}}== | ||
Line 103: | Line 116: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Endocrine therapy==== | |
*[[Megestrol acetate (Megace)]] 80 mg PO BID | *[[Megestrol acetate (Megace)]] 80 mg PO BID | ||
Line 132: | Line 145: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Endocrine therapy==== | |
*[[Megestrol acetate (Megace)]] 80 mg PO BID x 3 weeks, alternating with tamoxifen | *[[Megestrol acetate (Megace)]] 80 mg PO BID x 3 weeks, alternating with tamoxifen | ||
*[[Tamoxifen (Nolvadex)]] 20 mg PO BID x 3 weeks, alternating with megestrol | *[[Tamoxifen (Nolvadex)]] 20 mg PO BID x 3 weeks, alternating with megestrol | ||
Line 148: | Line 161: | ||
|} | |} | ||
===Regimen {{#subobject:af71e3|Variant=1}}=== | ===Regimen {{#subobject:af71e3|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.sciencedirect.com/science/article/pii/0090825889908391 Quinn et al. 1989] | ||
+ | |<span | ||
+ | style="background:#EEEE00; | ||
+ | padding:3px 6px 3px 6px; | ||
+ | border-color:black; | ||
+ | border-width:2px; | ||
+ | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/19/2/364.long Thigpen et al. 2001] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 155: | Line 180: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Endocrine therapy==== | ||
*[[Tamoxifen (Nolvadex)]] 20 mg PO BID | *[[Tamoxifen (Nolvadex)]] 20 mg PO BID | ||
− | ''' | + | '''Given until progression of disease or unacceptable toxicity''' |
===References=== | ===References=== | ||
− | # Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol. 1989 Jan;32(1):1-3. [http://www.ncbi.nlm.nih.gov/pubmed/2909443 PubMed] | + | # Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol. 1989 Jan;32(1):1-3. [http://www.sciencedirect.com/science/article/pii/0090825889908391 link to SD article] [http://www.ncbi.nlm.nih.gov/pubmed/2909443 PubMed] |
# Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Jan 15;19(2):364-7. [http://jco.ascopubs.org/content/19/2/364.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11208827 PubMed] | # Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Jan 15;19(2):364-7. [http://jco.ascopubs.org/content/19/2/364.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11208827 PubMed] | ||
=Adjuvant radiation & chemotherapy= | =Adjuvant radiation & chemotherapy= | ||
− | ==Cisplatin | + | ==RT -> Cisplatin & Doxorubicin {{#subobject:4d10f0|Regimen=1}}== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | |||
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy | RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy | ||
Line 189: | Line 215: | ||
|- | |- | ||
|} | |} | ||
− | + | ''Note: for chemotherapy, body surface area capped at 2.0 m<sup>2</sup>. Radiation is to begin within 8 weeks after surgery.'' | |
− | ==== | + | ====Radiotherapy==== |
*Radiation therapy to the pelvis, 1.8 Gy x 28 fractions (total dose: 50.4 Gy) | *Radiation therapy to the pelvis, 1.8 Gy x 28 fractions (total dose: 50.4 Gy) | ||
**Patients with positive para-aortic lymph nodes received 1.5 to 1.8 Gy x 24 to 29 fractions (total dose: 43.5 Gy) | **Patients with positive para-aortic lymph nodes received 1.5 to 1.8 Gy x 24 to 29 fractions (total dose: 43.5 Gy) | ||
− | '''6-week course, | + | '''6-week course, followed within 8 weeks by:''' |
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cisplatin (Platinol)]] 50 mg/ | + | *[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1, '''given second''' |
− | *[[Doxorubicin (Adriamycin)]] 45 mg/ | + | *[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 1, '''given first''' |
− | |||
− | Supportive medications: | + | ====Supportive medications==== |
− | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once | + | *G-CSF, either of the following: |
+ | **[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 2 to 11, or until ANC increases to 10,000 | ||
+ | **[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2 | ||
*[[Dexamethasone (Decadron)]] 10 mg IV once prior to chemotherapy | *[[Dexamethasone (Decadron)]] 10 mg IV once prior to chemotherapy | ||
*[[antiemesis|5-HT3 antagonist]] | *[[antiemesis|5-HT3 antagonist]] | ||
− | '''21-day cycle | + | '''21-day cycle for 6 cycles''' |
===References=== | ===References=== | ||
# Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar;112(3):543-52. Epub 2008 Dec 23. [http://www.gynecologiconcology-online.net/article/S0090-8258(08)00938-4/abstract link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459781/ link to PMC article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19108877 PubMed] | # Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar;112(3):543-52. Epub 2008 Dec 23. [http://www.gynecologiconcology-online.net/article/S0090-8258(08)00938-4/abstract link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459781/ link to PMC article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19108877 PubMed] | ||
− | ==Cisplatin, Doxorubicin, Paclitaxel | + | ==RT -> Cisplatin, Doxorubicin, Paclitaxel {{#subobject:24a846|Regimen=1}}== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
Line 234: | Line 261: | ||
|- | |- | ||
|} | |} | ||
− | + | ''Note: for chemotherapy, body surface area capped at 2.0 m<sup>2</sup>. Radiation is to start within 8 weeks after surgery.'' | |
− | ==== | + | ====Radiotherapy==== |
*Radiation therapy to the pelvis, 1.8 Gy x 28 fractions (total dose: 50.4 Gy) | *Radiation therapy to the pelvis, 1.8 Gy x 28 fractions (total dose: 50.4 Gy) | ||
**Patients with positive para-aortic lymph nodes received 1.5 to 1.8 Gy x 24 to 29 fractions (total dose: 43.5 Gy) | **Patients with positive para-aortic lymph nodes received 1.5 to 1.8 Gy x 24 to 29 fractions (total dose: 43.5 Gy) | ||
− | '''6-week course, | + | '''6-week course, followed within 8 weeks by:''' |
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Cisplatin (Platinol)]] 50 mg/ | + | *[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1, '''given second''' |
− | *[[Doxorubicin (Adriamycin)]] 45 mg/ | + | *[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 1, '''given first''' |
− | *[[Paclitaxel (Taxol)]] 160 mg/ | + | *[[Paclitaxel (Taxol)]] 160 mg/m<sup>2</sup> IV over 3 hours once on day 2 |
− | |||
− | Supportive medications | + | ====Supportive medications==== |
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 3 to 12, or until ANC increases to 10,000 | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 3 to 12, or until ANC increases to 10,000 | ||
*[[Dexamethasone (Decadron)]] 10 mg IV once prior to day 1 chemotherapy; [[Dexamethasone (Decadron)]] 20 mg once 5 to 12 hours prior to paclitaxel on day 2 | *[[Dexamethasone (Decadron)]] 10 mg IV once prior to day 1 chemotherapy; [[Dexamethasone (Decadron)]] 20 mg once 5 to 12 hours prior to paclitaxel on day 2 | ||
*[[antiemesis|5-HT3 antagonist]] | *[[antiemesis|5-HT3 antagonist]] | ||
− | '''21-day cycle | + | '''21-day cycle for 6 cycles''' |
===References=== | ===References=== | ||
Line 263: | Line 289: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen | + | ===Regimen {{#subobject:8159f4|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/29/16/2259.long Aghajanian et al. 2011] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 271: | Line 301: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Chemotherapy==== | ||
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | ||
Line 277: | Line 309: | ||
===References=== | ===References=== | ||
− | # Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 1;29(16):2259-65 | + | <!-- Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL. --> |
+ | # Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 1;29(16):2259-65. Epub 2011 May 2. [http://jco.ascopubs.org/content/29/16/2259.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21537039 PubMed] | ||
==Carboplatin (Paraplatin) {{#subobject:f9b8ad|Regimen=1}}== | ==Carboplatin (Paraplatin) {{#subobject:f9b8ad|Regimen=1}}== | ||
Line 285: | Line 318: | ||
|} | |} | ||
===Regimen {{#subobject:6a2df1|Variant=1}}=== | ===Regimen {{#subobject:6a2df1|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.ejcancer.info/article/S0959-8049%2802%2900504-X/abstract van Wijk et al. 2003] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 292: | Line 329: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Carboplatin (Paraplatin)]] 400 mg/ | + | |} |
− | **Dosage for patients with previously treated with chemotherapy is [[Carboplatin (Paraplatin)]] 300 mg/ | + | ====Chemotherapy==== |
+ | *[[Carboplatin (Paraplatin)]] 400 mg/m<sup>2</sup> IV over 30 minutes once on day 1 | ||
+ | **Dosage for patients with previously treated with chemotherapy is [[Carboplatin (Paraplatin)]] 300 mg/m<sup>2</sup> IV over 30 minutes once on day 1 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
Line 306: | Line 345: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen | + | ===Regimen {{#subobject:d48f39|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359926/ Pignata et al. 2007 (END-1)] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 314: | Line 357: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes once on day 1, '''given first''' | ||
+ | *[[Doxorubicin liposomal (Doxil)]] 40 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given second''' | ||
− | *[[ | + | ====Supportive medications==== |
− | + | *"No prophylactic use of [[Filgrastim (Neupogen)|G-CSF]] was recommended. In case of grade 4 neutropaenia, even without fever, therapeutic and prophylactic use of G-CSF was allowed." | |
− | '''28-day | + | '''28-day cycle for 3 to 6 cycles''' |
− | + | ''All patients received 3 cycles of therapy. If there was no unacceptable toxicity, patients with stable or responsive disease received an additional 3 cycles.'' | |
− | |||
===References=== | ===References=== | ||
− | # Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007 Jun 4;96(11):1639-43. Epub 2007 May 8. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359926/ link to | + | # Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007 Jun 4;96(11):1639-43. Epub 2007 May 8. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359926/ link to PMC article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17486128 PubMed] |
==Carboplatin & Paclitaxel {{#subobject:b0e21f|Regimen=1}}== | ==Carboplatin & Paclitaxel {{#subobject:b0e21f|Regimen=1}}== | ||
Line 331: | Line 378: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen #1 | + | ===Regimen #1 {{#subobject:7ab5c0|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.gynecologiconcology-online.net/article/S0090-8258(08)00083-8/abstract Pectasides et al. 2008] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 339: | Line 390: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 5 IV over 1 hour once on day 1, '''given second''' | ||
+ | *[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first''' | ||
− | + | '''21-day cycle for 6 to 9 cycles''' | |
− | |||
− | + | ===Regimen #2 {{#subobject:3a58ce|Variant=1}}=== | |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | ===Regimen #2 | + | |'''Study''' |
− | + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | |
− | <span | + | |- |
+ | |[http://jco.ascopubs.org/content/19/20/4048.long Hoskins et al. 2001] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 353: | Line 410: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Carboplatin (Paraplatin)]] AUC 5 to 7 IV once on day 1, given second | + | |} |
− | *[[Paclitaxel (Taxol)]] 175 mg/ | + | ====Chemotherapy==== |
+ | *[[Carboplatin (Paraplatin)]] AUC 5 to 7 IV once on day 1, '''given second''' | ||
+ | *[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first''' | ||
'''21-day cycles''' | '''21-day cycles''' | ||
− | ===Regimen #3 | + | ===Regimen #3 {{#subobject:100919|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://journals.lww.com/ijgc/Fulltext/2008/07000/Treatment_of_primary_advanced_and_recurrent.30.aspx Sorbe et al. 2008] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 367: | Line 430: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1 | + | |} |
− | *[[Paclitaxel (Taxol)]] 175 mg/ | + | ====Chemotherapy==== |
+ | *[[Carboplatin (Paraplatin)]] AUC 5 IV over 1 hour once on day 1 | ||
+ | *[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
'''21-day cycles''' | '''21-day cycles''' | ||
Line 375: | Line 440: | ||
===References=== | ===References=== | ||
# Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001 Oct 15;19(20):4048-53. [http://jco.ascopubs.org/content/19/20/4048.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11600606 PubMed] | # Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001 Oct 15;19(20):4048-53. [http://jco.ascopubs.org/content/19/20/4048.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11600606 PubMed] | ||
− | # Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008 May;109(2):250-4. Epub 2008 Mar 4. [http://www. | + | # Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008 May;109(2):250-4. Epub 2008 Mar 4. [http://www.gynecologiconcology-online.net/article/S0090-8258(08)00083-8/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18299146 PubMed] content property of [http://hemonc.org HemOnc.org] |
− | # Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):803-8. Epub 2007 Oct 18. [http://www.ncbi.nlm.nih.gov/pubmed/17944917 PubMed] | + | # Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):803-8. Epub 2007 Oct 18. [http://journals.lww.com/ijgc/Fulltext/2008/07000/Treatment_of_primary_advanced_and_recurrent.30.aspx link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17944917 PubMed] |
# '''Retrospective:''' Shechter-Maor G, Bruchim I, Ben-Harim Z, Altaras M, Fishman A. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer. Int J Gynecol Cancer. 2009 May;19(4):662-4. [http://journals.lww.com/ijgc/pages/articleviewer.aspx?year=2009&issue=05000&article=00029&type=abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19509567 PubMed] | # '''Retrospective:''' Shechter-Maor G, Bruchim I, Ben-Harim Z, Altaras M, Fishman A. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer. Int J Gynecol Cancer. 2009 May;19(4):662-4. [http://journals.lww.com/ijgc/pages/articleviewer.aspx?year=2009&issue=05000&article=00029&type=abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19509567 PubMed] | ||
Line 400: | Line 465: | ||
|- | |- | ||
|} | |} | ||
+ | ''Note: body surface area capped at 2.0 m<sup>2</sup>.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 1 hour once on day 1, '''given second''' | ||
+ | *[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1, '''given first''' | ||
+ | **Dosage for patients with previous pelvic radiation or who were >65 years old is [[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 1 | ||
− | + | '''21-day cycle for 7 cycles''' | |
− | |||
− | |||
− | |||
− | |||
− | '''21-day cycle | ||
===Regimen #2 {{#subobject:5baa3b|Variant=1}}=== | ===Regimen #2 {{#subobject:5baa3b|Variant=1}}=== | ||
Line 424: | Line 489: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Chemotherapy==== | |
− | *[[Cisplatin (Platinol)]] 50 mg/ | + | *[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once on day 1 of cycles 1 to 8 |
− | *[[Doxorubicin (Adriamycin)]] 60 mg/ | + | *[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1 of cycles 1 to 7 |
Supportive hydration: | Supportive hydration: | ||
*Normal saline at 500 mL/H for 2 hours prior to and after cisplatin | *Normal saline at 500 mL/H for 2 hours prior to and after cisplatin | ||
− | '''21-day cycle | + | '''21-day cycle for 8 cycles''' |
===References=== | ===References=== | ||
Line 458: | Line 523: | ||
|- | |- | ||
|} | |} | ||
+ | ''Note: body surface area capped at 2.0 m<sup>2</sup>.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 1 hour once on day 1, '''given second''' | ||
+ | *[[Doxorubicin (Adriamycin)]] 45 mg/m<sup>2</sup> IV once on day 1, '''given first''' | ||
+ | *[[Paclitaxel (Taxol)]] 160 mg/m<sup>2</sup> IV over 3 hours once on day 2 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | |||
− | Supportive medications | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 3 to 12 | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 3 to 12 | ||
− | '''21-day cycle | + | '''21-day cycle for 7 cycles''' |
===References=== | ===References=== | ||
Line 495: | Line 560: | ||
|- | |- | ||
|} | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV at an infusion rate of approximately 1 mg/min once per day on days 1 to 4, '''given first''' | ||
+ | *[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV over 1 hour once per day on days 1 to 4, '''given second together with [[Mesna (Mesnex)]]''' | ||
− | + | ====Supportive medications==== | |
− | + | *[[Mesna (Mesnex)]] 120 mg/m<sup>2</sup> IV bolus over 15 minutes once on day 1, then 1500 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours on days 1 to 4, '''given second together with [[Ifosfamide (Ifex)]]''' | |
− | *[[Mesna (Mesnex)]] 120 mg/ | ||
− | |||
− | |||
*Suggested hydration: 1 liter of NS or 1/2 NS given over several hours prior to chemotherapy | *Suggested hydration: 1 liter of NS or 1/2 NS given over several hours prior to chemotherapy | ||
− | '''21-day cycle | + | '''21-day cycle for 3 cycles''' |
===References=== | ===References=== | ||
Line 514: | Line 579: | ||
|} | |} | ||
===Regimen {{#subobject:b3c8fd|Variant=1}}=== | ===Regimen {{#subobject:b3c8fd|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.gynecologiconcology-online.net/article/S0090-8258(00)95827-X/abstract Dimopoulos et al. 2000] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 521: | Line 590: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 2 hours once on day 1, '''given second''' | ||
+ | *[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first''' | ||
− | + | ====Supportive medications==== | |
− | + | *[[Dexamethasone (Decadron)]] 20 mg PO/IV given twice, 12 and 6 hours prior to [[Paclitaxel (Taxol)]] | |
− | + | *Diphenhydramine (Benadryl) 25 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]] | |
− | + | *Ranitidine (Zantac) 50 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]] | |
− | + | *900 mL normal saline mixed with 100 mL mannitol given over 1 hour prior to [[Cisplatin (Platinol)]] | |
− | Supportive medications | + | *2 liters NS with potassium & magnesium after [[Cisplatin (Platinol)]] |
− | *[[Dexamethasone (Decadron)]] 20 mg PO/IV given twice, 12 and 6 hours prior to | ||
− | *Diphenhydramine (Benadryl) 25 mg IV once 30 minutes prior to | ||
− | *Ranitidine (Zantac) 50 mg IV once 30 minutes prior to | ||
− | *900 mL normal saline mixed with 100 mL mannitol given over 1 hour prior to | ||
− | *2 liters NS with potassium & magnesium after | ||
*"Appropriate [[antiemesis|antiemetics]]" | *"Appropriate [[antiemesis|antiemetics]]" | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 5 and continuing until WBC >10,000 | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 5 and continuing until WBC >10,000 | ||
+ | |||
+ | '''21-day cycle for up to 6 cycles''' | ||
===References=== | ===References=== | ||
− | # Dimopoulos MA, Papadimitriou CA, Georgoulias V, Moulopoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol. 2000 Jul;78(1):52-7. [http://www. | + | # Dimopoulos MA, Papadimitriou CA, Georgoulias V, Moulopoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol. 2000 Jul;78(1):52-7. [http://www.gynecologiconcology-online.net/article/S0090-8258(00)95827-X/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10873410 PubMed] |
==Dactinomycin (Cosmegen) {{#subobject:97a01a|Regimen=1}}== | ==Dactinomycin (Cosmegen) {{#subobject:97a01a|Regimen=1}}== | ||
Line 545: | Line 616: | ||
|} | |} | ||
===Regimen {{#subobject:2019ab|Variant=1}}=== | ===Regimen {{#subobject:2019ab|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.gynecologiconcology-online.net/article/S0090-8258(99)95652-4/abstract Moore et al. 1999] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 552: | Line 627: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Dactinomycin (Cosmegen)]] 2 mg/ | + | |} |
+ | ====Chemotherapy==== | ||
+ | *[[Dactinomycin (Cosmegen)]] 2 mg/m<sup>2</sup> IV over 15 minutes once on day 1 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
===References=== | ===References=== | ||
− | # Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999 Dec;75(3):473-5. [http://www. | + | # Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999 Dec;75(3):473-5. [http://www.gynecologiconcology-online.net/article/S0090-8258(99)95652-4/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10600310 PubMed] |
==Ifosfamide {{#subobject:b078a0|Regimen=1}}== | ==Ifosfamide {{#subobject:b078a0|Regimen=1}}== | ||
Line 582: | Line 659: | ||
|} | |} | ||
− | ''Note: GOG 161 specifies that PO [[Mesna (Mesnex)]] is to be taken in 3 divided doses, but only lists 2 time points for its use. | + | ''Note: GOG 161 specifies that PO [[Mesna (Mesnex)]] is to be taken in 3 divided doses, but only lists 2 time points for its use. The timing of the middle dose is estimated based on other references.'' |
− | *[[Ifosfamide (Ifex)]] 1600 mg/ | + | ====Chemotherapy==== |
− | **Dosage for patients with previous radiation is [[Ifosfamide (Ifex)]] 1200 mg/ | + | *[[Ifosfamide (Ifex)]] 1600 mg/m<sup>2</sup> IV once per day on days 1 to 3 |
+ | **Dosage for patients with previous radiation is [[Ifosfamide (Ifex)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 to 3 | ||
− | Supportive medications | + | ====Supportive medications==== |
*[[Mesna (Mesnex)]] 2000 mg IV over 12 hours once per day on days 1 to 3, starting 15 minutes before [[Ifosfamide (Ifex)]] | *[[Mesna (Mesnex)]] 2000 mg IV over 12 hours once per day on days 1 to 3, starting 15 minutes before [[Ifosfamide (Ifex)]] | ||
**Alternate PO dosing: [[Mesna (Mesnex)]] 1330 mg PO taken three times per day, 1 hour before, 4 hours after, and 8 hours after [[Ifosfamide (Ifex)]] (4000 mg total dose per day), on days 1 to 3 | **Alternate PO dosing: [[Mesna (Mesnex)]] 1330 mg PO taken three times per day, 1 hour before, 4 hours after, and 8 hours after [[Ifosfamide (Ifex)]] (4000 mg total dose per day), on days 1 to 3 | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day 4, to continue until ANC is greater than or equal to 2000 | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day 4, to continue until ANC is greater than or equal to 2000 | ||
− | '''21-day cycle | + | '''21-day cycle for 8 cycles''' |
===References=== | ===References=== | ||
Line 618: | Line 696: | ||
|} | |} | ||
− | ''Note: GOG 161 specifies that PO [[Mesna (Mesnex)]] is to be taken in 3 divided doses, but only lists 2 time points for its use. | + | ''Note: GOG 161 specifies that PO [[Mesna (Mesnex)]] is to be taken in 3 divided doses, but only lists 2 time points for its use. The timing of the middle dose is estimated based on other references.'' |
− | *[[Ifosfamide (Ifex)]] 1600 mg/ | + | ====Chemotherapy==== |
− | **Dosage for patients with previous radiation is [[Ifosfamide (Ifex)]] 1200 mg/ | + | *[[Ifosfamide (Ifex)]] 1600 mg/m<sup>2</sup> IV once per day on days 1 to 3 |
− | *[[Paclitaxel (Taxol)]] 135 mg/ | + | **Dosage for patients with previous radiation is [[Ifosfamide (Ifex)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 to 3 |
+ | *[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
− | Supportive medications | + | ====Supportive medications==== |
*[[Mesna (Mesnex)]] 2000 mg IV over 12 hours once per day on days 1 to 3, starting 15 minutes before [[Ifosfamide (Ifex)]] | *[[Mesna (Mesnex)]] 2000 mg IV over 12 hours once per day on days 1 to 3, starting 15 minutes before [[Ifosfamide (Ifex)]] | ||
**Alternate PO dosing: [[Mesna (Mesnex)]] 1330 mg PO taken three times per day, 1 hour before, 4 hours after, and 8 hours after [[Ifosfamide (Ifex)]] (4000 mg total dose per day), on days 1 to 3 | **Alternate PO dosing: [[Mesna (Mesnex)]] 1330 mg PO taken three times per day, 1 hour before, 4 hours after, and 8 hours after [[Ifosfamide (Ifex)]] (4000 mg total dose per day), on days 1 to 3 | ||
Line 631: | Line 710: | ||
*[[Cimetidine (Tagamet)]] 300 mg IV or [[Ranitidine (Zantac)]] 50 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]] | *[[Cimetidine (Tagamet)]] 300 mg IV or [[Ranitidine (Zantac)]] 50 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]] | ||
− | '''21-day cycle | + | '''21-day cycle for 8 cycles''' |
===References=== | ===References=== | ||
Line 641: | Line 720: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen #1 | + | ===Regimen #1 {{#subobject:a2c4fa|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.gynecologiconcology-online.net/article/S0090-8258(02)00068-9/abstract Lincoln et al. 2003] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 649: | Line 732: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
+ | **Dosage for patients with previous pelvic radiation is [[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
+ | **Dose of [[Paclitaxel (Taxol)]] can be changed to 135 or 110 mg/m<sup>2</sup> depending on toxicity | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | Supportive medications | ||
*[[Dexamethasone (Decadron)]] 20 mg PO/IV given twice, 12 and 6 hours prior to paclitaxel | *[[Dexamethasone (Decadron)]] 20 mg PO/IV given twice, 12 and 6 hours prior to paclitaxel | ||
*Diphenhydramine (Benadryl) 50 mg PO/IV once 30 minutes prior to paclitaxel | *Diphenhydramine (Benadryl) 50 mg PO/IV once 30 minutes prior to paclitaxel | ||
*Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to paclitaxel | *Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to paclitaxel | ||
− | ===Regimen #2 | + | '''21-day cycles''' |
− | + | ||
− | <span | + | ===Regimen #2 {{#subobject:f1656b|Variant=1}}=== |
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://annonc.oxfordjournals.org/content/7/8/861.long Lissoni et al. 1996] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 669: | Line 758: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | Supportive medications | ||
*Hydrocortisone (Cortef) 250 mg IV once 1 hour prior to paclitaxel | *Hydrocortisone (Cortef) 250 mg IV once 1 hour prior to paclitaxel | ||
*Chlorphenamine/chlorpheniramine (H1 blocker) 10 mg IM once 1 hour prior to paclitaxel | *Chlorphenamine/chlorpheniramine (H1 blocker) 10 mg IM once 1 hour prior to paclitaxel | ||
*Cimetidine (Tagamet) 300 mg IV once 1 hour prior to paclitaxel | *Cimetidine (Tagamet) 300 mg IV once 1 hour prior to paclitaxel | ||
− | ===Regimen #3 | + | '''21-day cycles''' |
− | + | ||
− | <span | + | ===Regimen #3 {{#subobject:68d2e|Variant=1}}=== |
+ | {| border="1" style="text-align:center;" !align="left" | ||
+ | |'''Study''' | ||
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://www.gynecologiconcology-online.net/article/S0090-8258(96)90227-9/abstract Ball et al. 1996] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 687: | Line 782: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | *[[Paclitaxel (Taxol)]] 250 mg/m<sup>2</sup> IV continuous infusion over 24 hours once on day 1 | ||
+ | **Dosage for patients with previous pelvic radiation is 200 mg/m<sup>2</sup> IV continuous infusion over 24 hours once on day 1 | ||
+ | **Dose can be changed to 200, 170, 135, 110 mg/m<sup>2</sup> depending on toxicity | ||
− | + | ====Supportive medications==== | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | Supportive medications | ||
*[[Dexamethasone (Decadron)]] 20 mg PO/IV given twice, 12 and 6 hours prior to paclitaxel | *[[Dexamethasone (Decadron)]] 20 mg PO/IV given twice, 12 and 6 hours prior to paclitaxel | ||
*Diphenhydramine (Benadryl) 50 mg PO/IV once 30 minutes prior to paclitaxel | *Diphenhydramine (Benadryl) 50 mg PO/IV once 30 minutes prior to paclitaxel | ||
*Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to paclitaxel | *Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to paclitaxel | ||
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day 3, 24 hours after chemotherapy, continued for at least 12 days or until two successive total leukocyte counts are 10,000 or greater, whichever comes last | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day starting on day 3, 24 hours after chemotherapy, continued for at least 12 days or until two successive total leukocyte counts are 10,000 or greater, whichever comes last | ||
+ | |||
+ | '''21-day cycles''' | ||
===References=== | ===References=== | ||
− | # Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Aug;62(2):278-81. [http://www. | + | # Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Aug;62(2):278-81. [http://www.gynecologiconcology-online.net/article/S0090-8258(96)90227-9/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8751561 PubMed] |
# Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol. 1996 Oct;7(8):861-3. [http://annonc.oxfordjournals.org/content/7/8/861.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8922203 PubMed] | # Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol. 1996 Oct;7(8):861-3. [http://annonc.oxfordjournals.org/content/7/8/861.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8922203 PubMed] | ||
− | # Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Mar;88(3):277-81. [http://www. | + | # Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Mar;88(3):277-81. [http://www.gynecologiconcology-online.net/article/S0090-8258(02)00068-9/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12648575 PubMed] |
==Temsirolimus (Torisel) {{#subobject:c19c6|Regimen=1}}== | ==Temsirolimus (Torisel) {{#subobject:c19c6|Regimen=1}}== | ||
Line 710: | Line 807: | ||
|[[#toc|back to top]] | |[[#toc|back to top]] | ||
|} | |} | ||
− | ===Regimen | + | ===Regimen {{#subobject:53c722|Variant=1}}=== |
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/29/24/3278.long Oza et al. 2011] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 718: | Line 819: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
+ | |} | ||
+ | ====Chemotherapy==== | ||
*[[Temsirolimus (Torisel)]] 25 mg IV over 30 minutes once per day on days 1, 8, 15, 22 | *[[Temsirolimus (Torisel)]] 25 mg IV over 30 minutes once per day on days 1, 8, 15, 22 | ||
Line 724: | Line 827: | ||
===References=== | ===References=== | ||
− | # Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011 Aug 20;29(24):3278-85 | + | # Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011 Aug 20;29(24):3278-85. Epub 2011 Jul 25. [http://jco.ascopubs.org/content/29/24/3278.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21788564 PubMed] |
==Topotecan (Hycamtin) {{#subobject:9a02a0|Regimen=1}}== | ==Topotecan (Hycamtin) {{#subobject:9a02a0|Regimen=1}}== | ||
Line 732: | Line 835: | ||
|} | |} | ||
===Regimen {{#subobject:1c2f98|Variant=1}}=== | ===Regimen {{#subobject:1c2f98|Variant=1}}=== | ||
− | + | {| border="1" style="text-align:center;" !align="left" | |
− | <span | + | |'''Study''' |
+ | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
+ | |- | ||
+ | |[http://jco.ascopubs.org/content/21/11/2110.long Wadler et al. 2003 (ECOG E3E93)] | ||
+ | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
padding:3px 6px 3px 6px; | padding:3px 6px 3px 6px; | ||
Line 739: | Line 846: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
− | + | |- | |
− | *[[Topotecan (Hycamtin)]] 1.5 mg/ | + | |} |
− | **Dosage for patients with previous pelvic radiation is | + | ====Chemotherapy==== |
+ | *[[Topotecan (Hycamtin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 to 5 | ||
+ | **Dosage for patients with previous pelvic radiation is 1.2 mg/m<sup>2</sup>, which can be increased to the 1.5 mg/m<sup>2</sup> dose in later cycles if there are no toxicities higher than grade 1 | ||
'''21-day cycles''' | '''21-day cycles''' | ||
Line 768: | Line 877: | ||
border-style:solid;">Phase III</span> | border-style:solid;">Phase III</span> | ||
|[[Uterine_cancer#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]] | |[[Uterine_cancer#Cisplatin_.26_Doxorubicin|Cisplatin & Doxorubicin]] | ||
− | |||
− | |||
|- | |- | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752331 Wolfson et al. 2007 (GOG 150)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752331 Wolfson et al. 2007 (GOG 150)] |
Revision as of 21:07, 21 August 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
35 regimens on this page
55 variants on this page
|
Endocrine therapy for endometrioid histologies
Anastrozole (Arimidex)
back to top |
Regimen
Study | Evidence |
Rose et al. 2000 | Phase II |
Endocrine therapy
- Anastrozole (Arimidex) 1 mg PO once per day
given until progression of disease or unacceptable toxicity
References
- Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000 Aug;78(2):212-6. link to original article contains verified protocol PubMed
Medroxyprogesterone acetate (MPA)
back to top |
Regimen
Study | Evidence | Comparator |
Thigpen et al. 1999 | Phase III | High-dose medroxyprogesterone acetate |
Endocrine therapy
- Medroxyprogesterone acetate (MPA) 200 mg PO once per day
Given until progression of disease or unacceptable toxicity
References
- Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999 Jun;17(6):1736-44. link to original article contains verified protocol PubMed
Medroxyprogesterone acetate & Tamoxifen
back to top |
Regimen
Study | Evidence |
Whitney et al. 2004 | Phase II |
Endocrine therapy
- Medroxyprogesterone acetate (MPA) 100 mg PO BID on even-numbered weeks (for example, week 2, 4, 6, etc.)
- Tamoxifen (Nolvadex) 20 mg PO BID
Given until progression of disease or unacceptable toxicity
References
- Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB; Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):4-9. link to original article contains verified protocol PubMed
Megestrol acetate (Megace)
back to top |
Regimen
Study | Evidence | Comparator |
Pandya et al. 2001 (E4882) | Randomized Phase II | Megestrol acetate & Tamoxifen |
Endocrine therapy
- Megestrol acetate (Megace) 80 mg PO BID
Given until progression of disease or unacceptable toxicity
References
- Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001 Feb;24(1):43-6. link to original article contains verified protocol PubMed
Megestrol acetate & Tamoxifen
back to top |
Regimen
Study | Evidence | Comparator |
Pandya et al. 2001 (E4882) | Randomized Phase II | Megestrol acetate |
Endocrine therapy
- Megestrol acetate (Megace) 80 mg PO BID x 3 weeks, alternating with tamoxifen
- Tamoxifen (Nolvadex) 20 mg PO BID x 3 weeks, alternating with megestrol
3-week courses of Megestrol acetate (Megace), alternating back and forth with 3-week courses of Tamoxifen (Nolvadex); given until progression of disease or unacceptable toxicity
References
- Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001 Feb;24(1):43-6. link to original article contains verified protocol PubMed
- Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W; Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):10-4. link to original article contains verified protocol PubMed
Tamoxifen (Nolvadex)
back to top |
Regimen
Study | Evidence |
Quinn et al. 1989 | Phase II |
Thigpen et al. 2001 | Phase II |
Endocrine therapy
- Tamoxifen (Nolvadex) 20 mg PO BID
Given until progression of disease or unacceptable toxicity
References
- Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol. 1989 Jan;32(1):1-3. link to SD article PubMed
- Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Jan 15;19(2):364-7. link to original article contains verified protocol PubMed
Adjuvant radiation & chemotherapy
RT -> Cisplatin & Doxorubicin
back to top |
RT: Radiation Therapy
Regimen
Study | Evidence | Comparator |
Homesley et al. 2008 (GOG 184) | Phase III | Cisplatin, Doxorubicin, Paclitaxel, RT |
Note: for chemotherapy, body surface area capped at 2.0 m2. Radiation is to begin within 8 weeks after surgery.
Radiotherapy
- Radiation therapy to the pelvis, 1.8 Gy x 28 fractions (total dose: 50.4 Gy)
- Patients with positive para-aortic lymph nodes received 1.5 to 1.8 Gy x 24 to 29 fractions (total dose: 43.5 Gy)
6-week course, followed within 8 weeks by:
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV once on day 1, given second
- Doxorubicin (Adriamycin) 45 mg/m2 IV once on day 1, given first
Supportive medications
- G-CSF, either of the following:
- Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 2 to 11, or until ANC increases to 10,000
- Pegfilgrastim (Neulasta) 6 mg SC once on day 2
- Dexamethasone (Decadron) 10 mg IV once prior to chemotherapy
- 5-HT3 antagonist
21-day cycle for 6 cycles
References
- Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar;112(3):543-52. Epub 2008 Dec 23. link to original article link to PMC article contains verified protocol PubMed
RT -> Cisplatin, Doxorubicin, Paclitaxel
back to top |
RT: Radiation Therapy
Regimen
Study | Evidence | Comparator |
Homesley et al. 2008 (GOG 184) | Phase III | Cisplatin, Doxorubicin, RT |
Note: for chemotherapy, body surface area capped at 2.0 m2. Radiation is to start within 8 weeks after surgery.
Radiotherapy
- Radiation therapy to the pelvis, 1.8 Gy x 28 fractions (total dose: 50.4 Gy)
- Patients with positive para-aortic lymph nodes received 1.5 to 1.8 Gy x 24 to 29 fractions (total dose: 43.5 Gy)
6-week course, followed within 8 weeks by:
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV once on day 1, given second
- Doxorubicin (Adriamycin) 45 mg/m2 IV once on day 1, given first
- Paclitaxel (Taxol) 160 mg/m2 IV over 3 hours once on day 2
Supportive medications
- Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 3 to 12, or until ANC increases to 10,000
- Dexamethasone (Decadron) 10 mg IV once prior to day 1 chemotherapy; Dexamethasone (Decadron) 20 mg once 5 to 12 hours prior to paclitaxel on day 2
- 5-HT3 antagonist
21-day cycle for 6 cycles
References
- Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar;112(3):543-52. Epub 2008 Dec 23. link to original article link to PMC article contains verified protocol PubMed
Advanced, recurrent, or metastatic disease
Bevacizumab (Avastin)
back to top |
Regimen
Study | Evidence |
Aghajanian et al. 2011 | Phase II |
Chemotherapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles, given until progression of disease or unacceptable toxicity
References
- Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 1;29(16):2259-65. Epub 2011 May 2. link to original article contains verified protocol PubMed
Carboplatin (Paraplatin)
back to top |
Regimen
Study | Evidence |
van Wijk et al. 2003 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) 400 mg/m2 IV over 30 minutes once on day 1
- Dosage for patients with previously treated with chemotherapy is Carboplatin (Paraplatin) 300 mg/m2 IV over 30 minutes once on day 1
28-day cycles
References
- van Wijk FH, Lhommé C, Bolis G, Scotto di Palumbo V, Tumolo S, Nooij M, de Oliveira CF, Vermorken JB; European Organization for Research and Treatment of Cancer. Gynaecological Cancer Group. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer. 2003 Jan;39(1):78-85. link to original article contains verified protocol PubMed
Carboplatin & Doxorubicin liposomal
back to top |
Regimen
Study | Evidence |
Pignata et al. 2007 (END-1) | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given first
- Doxorubicin liposomal (Doxil) 40 mg/m2 IV over 60 minutes once on day 1, given second
Supportive medications
- "No prophylactic use of G-CSF was recommended. In case of grade 4 neutropaenia, even without fever, therapeutic and prophylactic use of G-CSF was allowed."
28-day cycle for 3 to 6 cycles
All patients received 3 cycles of therapy. If there was no unacceptable toxicity, patients with stable or responsive disease received an additional 3 cycles.
References
- Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007 Jun 4;96(11):1639-43. Epub 2007 May 8. link to PMC article contains verified protocol PubMed
Carboplatin & Paclitaxel
back to top |
Regimen #1
Study | Evidence |
Pectasides et al. 2008 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 1 hour once on day 1, given second
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
21-day cycle for 6 to 9 cycles
Regimen #2
Study | Evidence |
Hoskins et al. 2001 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 to 7 IV once on day 1, given second
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
21-day cycles
Regimen #3
Study | Evidence |
Sorbe et al. 2008 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 1 hour once on day 1
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycles
References
- Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001 Oct 15;19(20):4048-53. link to original article contains verified protocol PubMed
- Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008 May;109(2):250-4. Epub 2008 Mar 4. link to original article contains verified protocol PubMed content property of HemOnc.org
- Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):803-8. Epub 2007 Oct 18. link to original article contains verified protocol PubMed
- Retrospective: Shechter-Maor G, Bruchim I, Ben-Harim Z, Altaras M, Fishman A. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer. Int J Gynecol Cancer. 2009 May;19(4):662-4. link to original article PubMed
Cisplatin & Doxorubicin
back to top |
Regimen #1
Study | Evidence | Comparator |
Fleming et al. 2004 (GOG 177) | Phase III | Cisplatin, Doxorubicin, Paclitaxel |
Note: body surface area capped at 2.0 m2.
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV over 1 hour once on day 1, given second
- Doxorubicin (Adriamycin) 60 mg/m2 IV once on day 1, given first
- Dosage for patients with previous pelvic radiation or who were >65 years old is Doxorubicin (Adriamycin) 45 mg/m2 IV once on day 1
21-day cycle for 7 cycles
Regimen #2
Study | Evidence | Comparator |
Randall et al. 2006 (GOG 122) | Phase III | Whole abdominal irradiation |
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV once on day 1 of cycles 1 to 8
- Doxorubicin (Adriamycin) 60 mg/m2 IV once on day 1 of cycles 1 to 7
Supportive hydration:
- Normal saline at 500 mL/H for 2 hours prior to and after cisplatin
21-day cycle for 8 cycles
References
- Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66. link to original article contains verified protocol PubMed
- Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44. Epub 2005 Dec 5. link to original article contains verified protocol PubMed
Cisplatin, Doxorubicin, Paclitaxel
back to top |
Regimen
Study | Evidence | Comparator |
Fleming et al. 2004 (GOG 177) | Phase III | Cisplatin & Doxorubicin |
Note: body surface area capped at 2.0 m2.
Chemotherapy
- Cisplatin (Platinol) 50 mg/m2 IV over 1 hour once on day 1, given second
- Doxorubicin (Adriamycin) 45 mg/m2 IV once on day 1, given first
- Paclitaxel (Taxol) 160 mg/m2 IV over 3 hours once on day 2
Supportive medications
- Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 3 to 12
21-day cycle for 7 cycles
References
- Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66. link to original article contains verified protocol PubMed
Cisplatin, Ifosfamide, Mesna (CIM)
back to top |
CIM: Cisplatin, Ifosfamide, Mesna
Regimen
Study | Evidence | Comparator |
Wolfson et al. 2007 (GOG 150) | Phase III | Whole abdominal irradiation |
Chemotherapy
- Cisplatin (Platinol) 20 mg/m2 IV at an infusion rate of approximately 1 mg/min once per day on days 1 to 4, given first
- Ifosfamide (Ifex) 1500 mg/m2 IV over 1 hour once per day on days 1 to 4, given second together with Mesna (Mesnex)
Supportive medications
- Mesna (Mesnex) 120 mg/m2 IV bolus over 15 minutes once on day 1, then 1500 mg/m2/day IV continuous infusion over 96 hours on days 1 to 4, given second together with Ifosfamide (Ifex)
- Suggested hydration: 1 liter of NS or 1/2 NS given over several hours prior to chemotherapy
21-day cycle for 3 cycles
References
- Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov;107(2):177-85. Epub 2007 Sep 5. link to PMC article contains verified protocol PubMed
Cisplatin & Paclitaxel
back to top |
Regimen
Study | Evidence |
Dimopoulos et al. 2000 | Phase II |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV over 2 hours once on day 1, given second
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
Supportive medications
- Dexamethasone (Decadron) 20 mg PO/IV given twice, 12 and 6 hours prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 25 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Ranitidine (Zantac) 50 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- 900 mL normal saline mixed with 100 mL mannitol given over 1 hour prior to Cisplatin (Platinol)
- 2 liters NS with potassium & magnesium after Cisplatin (Platinol)
- "Appropriate antiemetics"
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 5 and continuing until WBC >10,000
21-day cycle for up to 6 cycles
References
- Dimopoulos MA, Papadimitriou CA, Georgoulias V, Moulopoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol. 2000 Jul;78(1):52-7. link to original article contains verified protocol PubMed
Dactinomycin (Cosmegen)
back to top |
Regimen
Study | Evidence |
Moore et al. 1999 | Phase II |
Chemotherapy
- Dactinomycin (Cosmegen) 2 mg/m2 IV over 15 minutes once on day 1
28-day cycles
References
- Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999 Dec;75(3):473-5. link to original article contains verified protocol PubMed
Ifosfamide
back to top |
Regimen
Study | Evidence | Comparator |
Homesley et al. 2007 (GOG 161) | Phase III | Ifosfamide & Paclitaxel |
Note: GOG 161 specifies that PO Mesna (Mesnex) is to be taken in 3 divided doses, but only lists 2 time points for its use. The timing of the middle dose is estimated based on other references.
Chemotherapy
- Ifosfamide (Ifex) 1600 mg/m2 IV once per day on days 1 to 3
- Dosage for patients with previous radiation is Ifosfamide (Ifex) 1200 mg/m2 IV once per day on days 1 to 3
Supportive medications
- Mesna (Mesnex) 2000 mg IV over 12 hours once per day on days 1 to 3, starting 15 minutes before Ifosfamide (Ifex)
- Alternate PO dosing: Mesna (Mesnex) 1330 mg PO taken three times per day, 1 hour before, 4 hours after, and 8 hours after Ifosfamide (Ifex) (4000 mg total dose per day), on days 1 to 3
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting on day 4, to continue until ANC is greater than or equal to 2000
21-day cycle for 8 cycles
References
- Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 10;25(5):526-31. link to original article contains verified protocol PubMed
Ifosfamide & Paclitaxel
back to top |
Regimen
Study | Evidence | Comparator |
Homesley et al. 2007 (GOG 161) | Phase III | Ifosfamide |
Note: GOG 161 specifies that PO Mesna (Mesnex) is to be taken in 3 divided doses, but only lists 2 time points for its use. The timing of the middle dose is estimated based on other references.
Chemotherapy
- Ifosfamide (Ifex) 1600 mg/m2 IV once per day on days 1 to 3
- Dosage for patients with previous radiation is Ifosfamide (Ifex) 1200 mg/m2 IV once per day on days 1 to 3
- Paclitaxel (Taxol) 135 mg/m2 IV over 3 hours once on day 1
Supportive medications
- Mesna (Mesnex) 2000 mg IV over 12 hours once per day on days 1 to 3, starting 15 minutes before Ifosfamide (Ifex)
- Alternate PO dosing: Mesna (Mesnex) 1330 mg PO taken three times per day, 1 hour before, 4 hours after, and 8 hours after Ifosfamide (Ifex) (4000 mg total dose per day), on days 1 to 3
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting on day 4, to continue until ANC is greater than or equal to 2000
- Dexamethasone (Decadron) 20 mg PO/IV given twice, 12 and 6 hours prior to Paclitaxel (Taxol)
- Diphenhydramine (Benadryl) 50 mg IV once 30 minutes prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 300 mg IV or Ranitidine (Zantac) 50 mg IV once 30 minutes prior to Paclitaxel (Taxol)
21-day cycle for 8 cycles
References
- Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Ueland FR; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 10;25(5):526-31. link to original article contains verified protocol PubMed
Paclitaxel (Taxol)
back to top |
Regimen #1
Study | Evidence |
Lincoln et al. 2003 | Phase II |
Chemotherapy
- Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours once on day 1
- Dosage for patients with previous pelvic radiation is Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
- Dose of Paclitaxel (Taxol) can be changed to 135 or 110 mg/m2 depending on toxicity
Supportive medications
- Dexamethasone (Decadron) 20 mg PO/IV given twice, 12 and 6 hours prior to paclitaxel
- Diphenhydramine (Benadryl) 50 mg PO/IV once 30 minutes prior to paclitaxel
- Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to paclitaxel
21-day cycles
Regimen #2
Study | Evidence |
Lissoni et al. 1996 | Phase II |
Chemotherapy
- Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
Supportive medications
- Hydrocortisone (Cortef) 250 mg IV once 1 hour prior to paclitaxel
- Chlorphenamine/chlorpheniramine (H1 blocker) 10 mg IM once 1 hour prior to paclitaxel
- Cimetidine (Tagamet) 300 mg IV once 1 hour prior to paclitaxel
21-day cycles
Regimen #3
Study | Evidence |
Ball et al. 1996 | Phase II |
Chemotherapy
- Paclitaxel (Taxol) 250 mg/m2 IV continuous infusion over 24 hours once on day 1
- Dosage for patients with previous pelvic radiation is 200 mg/m2 IV continuous infusion over 24 hours once on day 1
- Dose can be changed to 200, 170, 135, 110 mg/m2 depending on toxicity
Supportive medications
- Dexamethasone (Decadron) 20 mg PO/IV given twice, 12 and 6 hours prior to paclitaxel
- Diphenhydramine (Benadryl) 50 mg PO/IV once 30 minutes prior to paclitaxel
- Cimetidine (Tagamet) 300 mg IV once 30 minutes prior to paclitaxel
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting on day 3, 24 hours after chemotherapy, continued for at least 12 days or until two successive total leukocyte counts are 10,000 or greater, whichever comes last
21-day cycles
References
- Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Aug;62(2):278-81. link to original article contains verified protocol PubMed
- Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol. 1996 Oct;7(8):861-3. link to original article contains verified protocol PubMed
- Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Mar;88(3):277-81. link to original article contains verified protocol PubMed
Temsirolimus (Torisel)
back to top |
Regimen
Study | Evidence |
Oza et al. 2011 | Phase II |
Chemotherapy
- Temsirolimus (Torisel) 25 mg IV over 30 minutes once per day on days 1, 8, 15, 22
28-day cycles, given until progression of disease, unacceptable toxicity, or patient decision
References
- Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011 Aug 20;29(24):3278-85. Epub 2011 Jul 25. link to original article contains verified protocol PubMed
Topotecan (Hycamtin)
back to top |
Regimen
Study | Evidence |
Wadler et al. 2003 (ECOG E3E93) | Phase II |
Chemotherapy
- Topotecan (Hycamtin) 1.5 mg/m2 IV once per day on days 1 to 5
- Dosage for patients with previous pelvic radiation is 1.2 mg/m2, which can be increased to the 1.5 mg/m2 dose in later cycles if there are no toxicities higher than grade 1
21-day cycles
References
- Wadler S, Levy DE, Lincoln ST, Soori GS, Schink JC, Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003 Jun 1;21(11):2110-4. link to original article contains verified protocol PubMed
Whole abdominal radiation (WAI)
back to top |
Regimen
Study | Evidence | Comparator |
Randall et al. 2006 (GOG 122) | Phase III | Cisplatin & Doxorubicin |
Wolfson et al. 2007 (GOG 150) | Phase III | CIM |
Not commonly used but was a comparator arm; here for reference purposes only.
References
- Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44. Epub 2005 Dec 5. link to original article contains verified protocol PubMed
- Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov;107(2):177-85. Epub 2007 Sep 5. link to PMC article contains verified protocol PubMed